South AfricaTuberculosis profile
Population  2016 56 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 23 (17–29) 41 (31–52)
Mortality (HIV+TB only) 100 (67–140) 181 (120–254)
Incidence  (includes HIV+TB) 438 (304–595) 781 (543–1 060)
Incidence (HIV+TB only) 258 (176–355) 461 (315–635)
Incidence (MDR/RR-TB)** 19 (12–25) 34 (22–45)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 27 (18–36) 154 (103–206) 182 (121–242)
Males 31 (20–41) 226 (150–301) 256 (171–342)
Total 58 (38–77) 380 (253–507) 438 (304–595)
TB case notifications, 2016  
Total cases notified 244 053
Total new and relapse 237 045
          - % tested with rapid diagnostics at time of diagnosis 69%
          - % with known HIV status 96%
          - % pulmonary 90%
          - % bacteriologically confirmed among pulmonary 67%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 54% (40–78)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.29 (0.17–0.43)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 135 169 59%
          - on antiretroviral therapy 119 213 88%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  8 200
(6 400–10 000)
Estimated % of TB cases with MDR/RR-TB 3.4% (2.5–4.3) 7.1% (4.8–9.5)  
% notified tested for rifampicin resistance     215 696
MDR/RR-TB cases tested for resistance to second-line drugs   11 903
Laboratory-confirmed cases MDR/RR-TB: 19 073, XDR-TB: 967
Patients started on treatment **** MDR/RR-TB: 11 192, XDR-TB: 628
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 81% 291 793
Previously treated cases, excluding relapse, registered in 2015 63% 5 441
HIV-positive TB cases registered in 2015 80% 167 335
MDR/RR-TB cases started on second-line treatment in 2014 54% 11 111
XDR-TB cases started on second-line treatment in 2014 27% 610
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 51%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions) 244
Funding source: 90% domestic, 10% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-17 Data: www.who.int/tb/data